Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02493257 · ClinicalTrials.gov registry record · Phase 2

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

A Phase 2 study of Nonallergic Irritant Rhinitis, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
1
Study location

NCT02493257 is a Phase 2 study of Nonallergic Irritant Rhinitis that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02493257, a Phase 2 study of Nonallergic Irritant Rhinitis, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The proposed study seeks to investigate the effect of intranasal capsaicin treatment in patient with Non-allergic irritant rhinitis (NAIR), as well as evaluate optical rhinometry (ORM) as a means to quantify symptomatic improvement in NAIR patients during and after treatment.

Interventions

  • DRUG Placebo
  • DRUG Capsaicin

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2014-10
Est. Completion 2019-08-02
Phase Phase 2

What the Registry Record Tells You About NCT02493257

The ClinicalTrials.gov registry entry for NCT02493257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Nonallergic Irritant Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02493257 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02493257 about?

NCT02493257 is a clinical study titled "Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis". The proposed study seeks to investigate the effect of intranasal capsaicin treatment in patient with Non-allergic irritant rhinitis (NAIR), as well as evaluate optical rhinometry (ORM) as a means to quantify symptomatic improvement in NAIR patients during and after treatment.

What is the current status of trial NCT02493257?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-10. Estimated completion is 2019-08-02.

What conditions does trial NCT02493257 study?

This clinical trial studies the following conditions: Nonallergic Irritant Rhinitis.

What interventions are being tested in trial NCT02493257?

The interventions under investigation include: Placebo (DRUG), Capsaicin (DRUG).

Who is sponsoring clinical trial NCT02493257?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02493257 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.